REG - HeiQ PLC - Commercial progress of HeiQ’s Hygiene technologies

HeiqAnnouncement

14/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220614:nRSN7146Oa&default-theme=true

RNS Number : 7146O  HeiQ PLC  14 June 2022

14 June 2022

HeiQ Plc

("HeiQ" or "the Company")

Commercial progress of HeiQ's Hygiene technologies across multiple markets

HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile
innovation that operates in high-growth markets, is pleased to provide an
update regarding the latest developments made within its Hygiene technology
business.

Following three strategic acquisitions in 2021, HeiQ strengthened its Hygiene
technology offering for healthcare, facility management, coatings,
antimicrobial plastics and textile industries with a range of pre and
probiotic, bio-based botanical solutions, including its HeiQ Synbio
technology. HeiQ now has one of the most sustainable product ranges in the
specialty hygiene ingredients industry today.

A Review on Antimicrobial Resistance (AMR) commissioned by the UK government
estimates that by 2050, there will be 10 million deaths globally per year due
to antimicrobial resistance(1). A McKinsey study predicted that consumer focus
on health and hygiene, increased due to the recent pandemic, will endure in
the long term(2). With this in mind, HeiQ has made it one of its business
imperatives to introduce effective and sustainable hygiene solutions to
healthcare facilities and across the markets it operates in.

Strong independent validation of HeiQ Synbio cleaning performance probiotic
cleaning compared to conventional disinfectants in preventing AMR in hospitals

 

·    A recent study by the Charité-Universitätsmedizin Hospital in
Berlin found that European hospitals could save €760 million a year in
medical costs related to HAI. through switching to probiotic cleaning products
such as HeiQ Synbio from traditional disinfectants*.

 

·    HeiQ Synbio is proven to reduce AMR on hospital surfaces by up to
99.9%(3) and to reduce incidences of HAI by up to 52%(4,5) more effectively
compared with traditional disinfectants.

 

·    As a result of using probiotic cleaning products such as HeiQ Synbio,
experts have demonstrated that hospitals could see a reduction in costs
associated with HAI by up to 75%(4)(.)

 

Positive implications on HeiQ's business

 

·    Following the publication of the results from the study in
Charité-Universitätsmedizin Hospital, HeiQ relaunched the extended HeiQ
Synbio range at Interclean Amsterdam, the world's largest professional
cleaning and hygiene exhibition, and held a seminar on Spectacular
Sanitization of Healthcare Facilities.

 

·    HeiQ expects the EU to follow these positive scientific results and
revise their facility management protocol guidelines for hospitals which will
accelerate the adoption of the study recommendations. The
Charité-Universitätsmedizin Hospital has started purchasing HeiQ Synbio
cleaners.

 

 

Commercial progress of HeiQ's broad Hygiene technologies across multiple
markets

 

 

·    HeiQ recently launched its innovative HeiQ Sanpure BIO, a 100%
bio-based cleaner for facility management which enables less frequent
cleaning, and secured Engie Facility Management (part of Engie SA, a French
group with €60 bn turnover in 2019) as its first adopter.

 

·    Greenspeed, HeiQ's main distributor to hospitals in Benelux
countries, has successfully launched two further new HeiQ Synbio enabled
products.

 

·    Helly Hansen (part of Mark's Canada, a company valued at CA$1.2 bn)
launched HeiQ Viroblock treated gowns with 99% reduction claims for
staphylococcus aureus & Sars-Cov-2 with a medical device categorisation
for hospitals in Canada.

 

·    Field trials conducted for Malteser International - an international
non-governmental humanitarian aid agency like the Red Cross - demonstrates
that HeiQ Sanpure Permanent Coating reduces bacterial loads in ambulances by
more than 50%. HeiQ has developed critical healthcare surfaces.

 

·    HeiQ filed for a new HeiQ Synbio patent for textile applications
focusing on home textiles with anti-allergen and odour control claims. A
product launch is scheduled for Q3.

 

·    HeiQ and its long-term research partner Patagonia announced the
launch of HeiQ Fresh MNT, a jointly-developed odour control textile technology
based on renewably-sourced mint oil, complementing the Company's HeiQ Fresh
family of sustainable odour management technologies consisting of
mineral-based HeiQ Fresh HAX and bio-based HeiQ Fresh FFL.

 

 

HeiQ Group Co-Founder and CEO, Carlo Centonze said:

 

"I am delighted to report that momentum across our Hygiene technology offering
continues at an extremely high pace, with our products independently proven to
solve devastating issues which are affecting people and medical facilities
worldwide. The natural ingredients used in our products mean that they are not
only capable of saving lives and costs, but that they can do so in a way which
does not harm the environment. This is causing governments to reassess their
guidance, which demonstrates the importance of our findings and the scale of
the issues we are solving.

 

"New contracts have been signed and brands brought on board, and we have also
launched new products and patent applications to solidify the future potential
of our product range, which is the strongest and most sustainable in the
specialty hygiene ingredients industry. This is an exciting time for our
Hygiene technology business and with a strong pipeline in place, we look
forward to sharing future updates with our shareholders."

 

Footnotes

*Calculation based on 52% reduction of HAI incidence by HeiQ Synbio cleaning
performance probiotic cleaning(6), impacting the EUR1.46 Bn/year expenditure
in AMR (2015-2050) and non-resistant HAIs, estimated by the European Center
for Disease Control (ECDC)(7) and the Italian Ministry of Health(8)

 

1) Antimicrobial Resistance: Tackling a crisis for the health and wealth of
nations. The Review on Antimicrobial Resistance Chaired by Jim O'Neill
December 2014

2) McKinsey & Company, How COVID-19 is changing consumer behavior - now
and forever, 2020

3) Klassert, T. E. et al. Comparative analysis of surface sanitization
protocols on the bacterial community structures in the hospital environment.
Clin. Microbiol. Infect. 0, (2022).

4) Caselli, E. et al. Impact of a probiotic-based hospital sanitation on
antimicrobial resistance and HAI-associated antimicrobial consumption and
costs: a multicenter study. Infect. Drug Resist. 12, 501-510 (2019).

5) Tarricone, R., Rognoni, C., Arnoldo, L., Mazzacane, S. & Caselli, E. A
Probiotic-Based Sanitation System for the Reduction of Healthcare Associated
Infections and Antimicrobial Resistances: A Budget Impact Analysis. Pathogens
9, 502 (2020)

6) Caselli, E. et al. Impact of a probiotic-based hospital sanitation on
antimicrobial resistance and HAI-associated antimicrobial consumption and
costs: a multicenter study. Infect. Drug Resist. 12, 501-510 (2019).

7) Infographic: Healthcare-associated infections - a threat to patient safety
in Europe. European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en/publications-data/infographic-healthcare-associated-infections-threat-patient-safety-europe
(2018).

8) Salute, M. della. Antibiotico-resistenza nel settore umano.
https://www.salute.gov.it/portale/antibioticoresistenza/dettaglioContenutiAntibioticoResistenza.jsp?lingua=italiano&id=5282&area=antibiotico-resistenza&menu=vuoto&tab=1
(https://www.salute.gov.it/portale/antibioticoresistenza/dettaglioContenutiAntibioticoResistenza.jsp?lingua=italiano&id=5282&area=antibiotico-resistenza&menu=vuoto&tab=1)
.

 

For further information, please visit www.heiq.com/investors
(http://www.heiq.com/investors) or contact:

 HeiQ Plc                                                +41 56 250 68 50

 Carlo Centonze (CEO)
 HeiQ Investors Relations Service Desk                   https://heiq.atlassian.net/servicedesk
                                                         (https://heiq.atlassian.net/servicedesk/customer/portal/11/group/22/create/92)

                                                         /customer/portal/11/group/22/create/92
                                                         (https://heiq.atlassian.net/servicedesk/customer/portal/11/group/22/create/92)

 Cenkos Securities plc (Joint Broker)                    +44 (0) 207 397 8900

 Stephen Keys / Callum Davidson
 SEC Newgate (Media Enquiries)                           +44 (0) 20 3757 6882

 Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton   HeiQ@secnewgate.co.uk

 

About HeiQ

HeiQ Plc is a purpose-led IP creator for novel materials. It develops and
commercialises technologies that make textiles, surfaces and materials more
hygienic, protective, comfortable and resource efficient. And critically, they
make them more sustainable too.

HeiQ offers technologies in 4 main functions to customers and consumers and
delivers them in 4 forms (our "4x4" approach). It sells these technologies in
a range of different forms - either as ingredients, materials, finished goods
or on a trademark licensing basis. Its added functionalities provide
product-developers with a valuable USP, which means that HeiQ's end users
include over 300 major brands.

During its 17-year history, HeiQ has built long-standing relationships with
clients all over the world and secured an established position in the textile
sector. In recent years, it has expanded its offerings to other industries to
also address material innovations in healthcare, water treatment, industrial
laundry, detergents, paints and coatings, plastics and packaging.

HeiQ employs over 300 people, based in 14 offices, 8 R&D hubs and 7
manufacturing facilities around the world. Over 20 distributors complete its
global presence to serve over 50 countries.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUPCQUPPGQW